- UroToday Home
- Recent Abstracts
- Urologic Oncology
Renal Cancer
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.
February 23, 2022
Investigating Urinary Circular RNA Biomarkers for Improved Detection of Renal Cell Carcinoma.
February 22, 2022
The prognostic impact of Claudin 6 in papillary renal cell carcinoma.
February 21, 2022
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
February 21, 2022
Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
February 21, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
February 18, 2022
Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial.
February 18, 2022
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?
February 17, 2022
Systematic Review With Meta-Analysis: Diagnostic, Prognostic and Clinicopathological Significance of CircRNA Expression in Renal Cancer.
February 16, 2022
Perspectives on the Role of Biopsy for Management of T1 Renal Masses: Survey Results from Two Regional Quality Improvement Collaboratives.
February 15, 2022
Partial vs. radical nephrectomy in non-metastatic pT3a kidney cancer patients: a population-based study.
February 15, 2022
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point.
February 14, 2022
C-reactive protein kinetics to predict recurrence of high-risk renal cell carcinoma after radical surgery.
February 14, 2022
Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy.
February 11, 2022